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by immunohistochemistry using tissue microarrays in a 
contemporary and homogeneous cohort of OAC patients 
(n = 128) undergoing curative treatment.
Results Multivariate analysis identified three independ-
ent prognostic factors for improved cancer-specific survival 
(CSS): increased CD8+ TILs (p = 0.003), completeness 
of resection (p < 0.0001) and lower pathological N stage 
(p < 0.0001). Independent prognostic factors for favour-
able disease-free survival included surgery-only treat-
ment (p = 0.015), completeness of resection (p = 0.001), 
increased CD8+ TILs (p < 0.0001) and reduced pathologi-
cal N stage (p < 0.0001). Higher levels of TILs in the path-
ological specimen were associated with significant patho-
logical response to neoadjuvant chemotherapy (NAC). On 
multivariate analysis increased levels of CD4+ (p = 0.017) 
and CD8+ TILs (p = 0.005) were associated with signifi-
cant local tumour regression and lymph node downstaging, 
respectively.
Discussion Our results establish an association of TILs 
and survival in OAC, as seen in other solid tumours, and 
identify particular TIL subsets that are present at higher 
levels in patients who responded to NAC compared to 
non-responders. These findings highlight potential thera-
peutic strategies in EAC based on utilising the host immu-
nological response and highlight the immune responses 
biomarker potential.
Abstract 
Background Oesophageal adenocarcinoma (OAC) is 
increasingly common in the west, and survival remains 
poor at 10–15 % at 5 years. Immune responses are increas-
ingly implicated as a determining factor of tumour pro-
gression. The ability of lymphocytes to recognise tumour 
antigens provides a mechanism for a host immune attack 
against cancer providing a potential treatment strategy.
Materials and Methods Tumour infiltrating lymphocytes 
(TILs: CD3+, CD4+, CD8+ and FOXp3+) were assessed 
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Abbreviations
ASA  American Society of Anesthesiologists physical 
status classification system
CD  Cluster of differentiation
CSS  Cancer-specific survival
DFS  Disease-free survival
FOXp3  Forkhead box p3
LN  Lymph node
NAC  Neoadjuvant chemotherapy
NLR  Neutrophil/lymphocyte ratio
OAC  Oesophageal adenocarcinoma
OSCC  Oesophageal squamous cell carcinoma
PARP  Poly-ADP ribose polymerase inhibitors
TIL  Tumour infiltrating lymphocyte
TMA  Tissue microarray
TNM  The TNM classification of malignant tumours
TRG  Tumour regression grade
WCC  White cell count
Introduction
Virchow first described the association of lymphocyte infil-
tration with solid tumours in 1863 [1]. Immune responses 
against malignant cells, whether systemic or within the 
tumour microenvironment, are increasingly implicated as 
a determining factor in tumour progression [2]. The most 
comprehensive studies, to establish this hallmark of cancer 
[3], have been in colorectal tumours [4]. Specific tumour 
infiltrating lymphocyte (TIL) subsets communicate and 
function to affect tumour growth, and the balance of these 
effects leads to either tumour regression or tumour promo-
tion. An anti-tumour effect is mediated by the combina-
tion of cancer cell lysis and the production of cytotoxic 
cytokines, supported by cluster of differentiation (CD)4+ 
T helper cells. In contrast, T regulatory cells, Forkhead 
box P3+ (FOXp3+) T cells, act to suppress the immune 
response of other cells and so affect the inflammatory pro-
cess indirectly [2]. Therefore, understanding the impact of 
specific subsets of immune cells that infiltrate tumours is 
important for making rational decisions in the development 
of targeted therapies.
Oesophageal adenocarcinoma (OAC) is becoming 
increasingly common in the Western world, and despite 
a variety of strategies to improve outcome [5], survival 
remains poor at 10–15 % at 5 years [6]. Radical treat-
ment with curative intent includes neoadjuvant therapy 
and oesophagogastrectomy. Neoadjuvant chemotherapy 
(NAC) delivers improved survival in a small percentage of 
patients, in whose tumours there is a significant pathologi-
cal response to treatment [7]. However, approximately two-
third of patients present with advanced, incurable disease at 
diagnosis. Biological therapies such as growth factor block-
ers, poly-ADP ribose polymerase (PARP) inhibitors, vac-
cines and monoclonal antibodies are being evaluated and 
are yet to enter routine clinical practice [8]. The rapid rise 
in incidence of OAC in the west means that novel therapies 
are urgently required, either as single agents or for use in 
combination with conventional treatments.
In particular, the ability of CD8+ lymphocytes to rec-
ognise tumour antigens has been well documented [9], 
and tumour regression is observed when tumour-reactive 
T lymphocytes invade cancers [10]. Before considering 
immune therapies as a potential treatment in OAC, it is 
important to understand whether immune cells are present 
in OAC, in which subsets of cells are observed and whether 
or not they have prognostic significance.
The effects of TILs have been studied in a range of 
solid tumours, and high TIL density correlates with bet-
ter survival (reviewed in [11]). A few initial studies have 
examined the association of TILs in OAC with prognosis 
[12, 13]. These studies have provided conflicting results, 
and no study has assessed TIL density in resected tumours 
after NAC and whether or not there is a link to outcome. 
Schumacher et al. observed intratumoural CD8+ T cell 
infiltration to correlate with improved survival in a small 
heterogeneous cohort of OAC (n = 37) and oesophageal 
squamous cell carcinoma (OSCC) (n = 33) patients [14]. 
Additional studies have shown that the overall grade of TIL 
density at the invasive margin correlates with improved sur-
vival in patients with gastroesophageal cancer [12]. In con-
trast, Zingg et al. did not find any independent associations 
between differing TIL subsets and survival in OAC patients 
who received multimodal therapy with either neoadjuvant 
chemoradiotherapy or surgery alone. However, they did 
demonstrate in univariate analyses that particular subtypes 
of TIL conferred a better survival when dichotomised at 
median counts (CD3+, CD8+, FOXp3+, CD8+:CD4+) 
[15]. Therefore, the prognostic value of TILs in OAC 
remains to be established and the composition of TIL den-
sity following NAC in OAC is yet to be assessed.
In this study, we assessed the immune infiltrate in a 
large contemporary cohort of OAC (n > 120) to identify 
association with survival and clinicopathological disease 
characteristics. Specifically, we examined TILs, as their 
presence would suggest that active immunotherapy might 
be attractive in this condition. A link between pre-existing 
immunity might then also allow us to stratify patients into 
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groups, more or less likely to benefit from immunomodula-
tion such as checkpoint blockade, which allows a release of 
pre-existing immune responses for clinical benefit. In addi-
tion, we analyse TIL frequencies following NAC and assess 
the relationship between TILs and disease outcome.
Materials and methods
Patient selection
A prospectively collected database of consecutive patients 
undergoing oesophagogastric resection for OAC treated at 
University Hospital Southampton NHS Foundation Trust 
between January 2005 and December 2010 was reviewed. 
Patients were excluded from the study if they had achieved 
a complete pathological response (tumour regression grade 
(TRG) 1; no residual tumour), if they died post-operatively 
as an inpatient, or if no histopathological tissue was avail-
able. Ethical approval was received from the Southampton 
and South West Hampshire Research and Ethics Commit-
tee (REC 09/H0504/66) and approved by the local research 
and development department (RHM CAN0649).
Patient clinical, pathological, treatment and follow‑up 
characteristics
All patients (n = 128, Table 1) were discussed at a specialist 
multidisciplinary team meeting. Standard staging investiga-
tions included endoscopic ultrasonography, high-resolution 
computed tomography, integrated fluorodeoxyglucose 
positron emission tomography/computed tomography and 
staging laparoscopy, where indicated and were uniformly 
applied during the study interval. Patients considered suit-
able for potential surgical resection with tumours staged as 
T2 N0 M0 or above were considered for NAC.
NAC consisted of three 21-day cycles of anthracycline, 
platinum and fluoropyrimidine: ECF (epirubicin 50 mg/m2, 
cisplatin 60 mg/m2, both intravenously on day 1 and venous 
infusion 5-FU 200 mg/m2 per day for 21 days), ECX (epi-
rubicin 50 mg/m2, cisplatin 60 mg/m2, both intravenously 
on day 1 and capecitabine 625 mg/m2 orally twice daily for 
21 days) or EOX (epirubicin 50 mg/m2 i.v. bolus and oxali-
platin 130 mg/m2 i.v. infusion over 2 h on day 1, capecit-
abine 625 mg/m2 orally twice daily for 21 days).
Pathological status after chemotherapy was assessed 
using the TRG system developed by Mandard et al. [16] 
who scored regression based on the degree of fibrosis and 
number of residual cancer cells (TRG 1–5). TRG was 
scored by specialist gastrointestinal pathologists, initially 
by one pathologist (Adrian C Bateman) prior to its intro-
duction by all pathologists as part of routine pathological 
reporting. All dissected lymph nodes were stained with 
Table 1  Clinicopathological characteristics of patient cohort for 
which formed TMAs
Values in parentheses are percentages unless indicated
ASA American Society of Anesthesiologists physical status classifi-
cation system
* Values in parentheses are range
n = 128
Operation age* 67.77 (45.48–85.41)
Sex ratio (M:F) 112:16
ASA
 1 13 (10.2)
 2 93 (72.4)
 3 22 (17.3)
Tumour site
 Lower 1/3 46 (35.9)
 OGJ—S1 25 (19.5)
 OGJ—S2 26 (20.3)
 OGJ—S3 31 (24.2)
Type
 AC 128 (100)
pT or ypT
 T1 29 (22.7)
 T2 30 (23.4)
 T3 65 (50.8)
 T4 4 (3.1)
pN or ypN
 N0 59 (46.1)
 N1 28 (21.9)
 N2 21 (16.4)
 N3 20 (15.6)
pM or ypM
 M0 125 (97.7)
 M1 3 (2.3)
Resection clearance (R0) 104 (81.3)
Vascular invasion 51 (39.8)
Lymphatic invasion 21 (16.4)
Perineural invasion 17 (13.3)
Neoadjuvant chemotherapy 76 (59.4)
Neoadjuvant regime
 ECX 64 (50)
 EOX 10 (7.8)
 ECF 2 (1.6)
Tumour regression grade
 1 0 (0)
 2 11 (8.6)
 3 10 (7.8)
 4 29 (22.7)
 5 26 (20.3)
 Not assessed 0 (0)
 Surgery only 52 (40.6)
Nodal downstaging 30/76 (39.5)
 Cancer Immunol Immunother
1 3
haematoxylin and eosin and microscopically analysed for 
metastatic disease. Lymph node downstaging was defined 
by lymph nodes being positive for signs of cancer (cN+) at 
diagnosis, assessed radiologically (computed tomography, 
positron emission tomography, endoscopic ultrasonogra-
phy) and then pathologically recorded as the lymph nodes 
showing no signs of cancer spread (ypN0) after NAC given 
prior to surgery as previously described [17].
Surgery was performed after initial staging or 4–6 weeks 
following NAC as previously described [18].
Data recorded included demographics, tumour charac-
teristics, resection type and histopathological analysis of 
the surgical specimen. The TNM classification of malig-
nant tumours (TNM) 7 was used to report tumour stage 
after analysis of pathology reports [19]. Pathological 
tumour clearance (“R”-status) was determined according to 
the Royal College of Pathologists’ guidance [20].
All patients were cared for by a specialist oesophagogas-
tric team as previously described [18]. Recurrence of disease 
during follow-up was defined as the first site or sites of recur-
rence with radiological or pathological confirmation. Cancer-
specific survival (CSS) was defined as time of operation to 
death in the absence of other causes of death. For assessment 
of disease-free survival (DFS), recurrence was defined as 
time from operation to development of local, nodal (regional) 
and distant metastasis (whichever occurred first).
Immunohistochemistry
Post-operative tumour histology was reviewed by patholo-
gists (Gareth J. Thomas and Adrian C. Bateman) blinded 
to treatment and outcome, and a suitable paraffin block 
was selected. Tissue microarrays (TMAs) were constructed 
using triplicate, randomly selected, paraffin-embedded 
1-mm tumour cores (Aphelys Minicore 2, Mitogen, 
Harpenden, UK). To assess the immune infiltrate, 4-µm 
sections of TMA blocks were used. Automated immu-
nostaining (Ventana XT, Ventana, Tucson, AZ, USA) 
was performed in a clinical pathology accredited cellu-
lar pathology department using antibodies optimised to 
national diagnostic standards (National External Quality 
Assessment Service). Antibodies to assess antigens were as 
follows: CD3, pan T cells; CD4, helper T cells; CD8, cyto-
toxic T cells (all from Novocastra, Milton Keynes, UK); 
and FOXp3, regulatory T cells (eBioscience, Hatfield, UK). 
Patients (n = 13) with complete pathological response 
(TRG 1) were excluded due to the inability to assess TILs 
due to the lack of tumour.
Immunohistochemical evaluation
All sections were digitally image captured to enable sec-
tions to be scored under the supervision of an experienced 
pathologist (Gareth J. Thomas). Three high-powered fields 
(×400 magnification) with the highest density of the 
marker of interest were scored, with a mean taken, provid-
ing a total scoring area of 0.1944 mm2. This is in keeping 
with previous studies assessing intratumoural immune infil-
tration [21].
Training of the observers was undertaken on a series 
of OACs from the TMA. A total of 25 randomly selected 
patients from the total cohort were used to assess the intrao-
bserver and interobserver variation in the TIL scoring. Two 
observers (Fergus Noble and Leo M. Matthews) assessed 
the TIL infiltrate independently and without knowledge of 
clinicopathological information. The interobservers’ intra-
class correlation coefficient was >0.7 and was considered 
acceptable in keeping with previous studies [22]. Fergus 
Noble scored all slides, and these data were used in the 
analysis [23].
Following scoring, TIL density data were grouped to 
facilitate some of the statistical analysis. This was estab-
lished using justifiable cut-offs (high–low/either side of the 
median).
Preoperative systemic inflammatory and nutritional 
blood‑borne markers analysed
Preoperative blood samples were taken for routine labora-
tory analysis of full blood count (FBC) and albumin in the 
preoperative period (within 1 week of resection). The white 
cell count (WCC) (reference range 4.0–11.0 × 109/l), 
platelet count (reference range 150–400 × 109/l), neutro-
phil count (reference range 2.0–7.5 × 109/l) and lympho-
cyte count (reference range 1.5–4.0 × 109/l) were analysed 
with an automated haematological blood analyser (Sysmex 
TS-500 (Sysmex UK Ltd)). Serum concentrations of albu-
min (normal range: 35–48 g/l) were measured in an auto-
analyser (UniCel DxC800 (Beckmann Coulter Inc)). The 
coefficient of variation for these methods, over the range 
of measurement, was less than 2 % as established by rou-
tine quality control. All patients were free from infection 
at the time of blood collection as determined by clinical 
assessment.
The neutrophil/lymphocyte ratio (NLR) was calculated 
by dividing the absolute neutrophil count by the absolute 
lymphocyte count (reference range 0.5–5) and represents 
an inexpensive measure of systemic inflammation [24].
Statistical analysis
Descriptive data are represented as median and range 
unless indicated. The Kruskal–Wallis, Mann–Whitney U 
and Pearson’s Chi-squared tests were used as appropri-
ate for comparisons of groups. Kaplan–Meier, univariate 
and multivariate Cox logistic regression modelling were 
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used to assess the relationship between immune infiltra-
tion with CSS, DFS and response to NAC as outcomes. All 
factors that showed statistical significance on univariate 
analysis were entered to derive the final model using the 
backward stepwise likelihood ratio method. CSS and DFS 
curves of the patients were plotted by using the Kaplan–
Meier method and analysed using the log-rank test. Strati-
fied analyses were performed based on receipt of NAC and 
pathological response to chemotherapy. A p value < 0.05 
was considered statistically significant for all tests. Statis-
tical analysis was performed with statistical package for 
the social sciences version 21 (SPSS®, Chicago, Illinois, 
USA).
Results
Study patients
A total of 128 patients were included in the study with a 
median follow-up of 3.5 years (95 % CI 2.629–4.342). The 
study population had a median age at operation of 68 years 
(range, 46–85 years) and was predominately male (88 %). 
The majority had pathologically advanced staged, pT/
ypT3 (51 %) and node-positive disease (54 %), which were 
located either at the oesophagogastric junction (64 %) or in 
the lower oesophagus (36 %).
In total, 76 (59.4 %) patients received multimodal 
therapy, consisting of NAC and surgery, with 52 (40.6 %) 
patients proceeding directly to surgery alone. Of the 
patients who received multimodal therapy, 11 (15 %) 
patients had a significant local tumoural response (TRG 
2), and 30 (40 %) patients had a significant lymph node 
response (lymph node downstaging: cN+ to ypN0) to 
NAC.
Detailed patient characteristics and clinical and patho-
logical outcomes are summarised in Table 1.
The relationship of intratumoural infiltrating 
lymphocytes and clinicopathological characteristics
Representative TIL staining is shown in supplemental Fig-
ure S1. The relationship of patient and tumour characteris-
tics to TILs is presented in supplemental Table S1 and sup-
plemental Table S2, respectively.
A lower TIL density, across all subsets, was significantly 
associated with increasing stage of disease (T and N stage) 
and with vascular, lymphatic and perineural invasion (sup-
plemental Table S2).
Higher TIL counts were observed in female compared 
to male patients (supplemental Table S1). This was statisti-
cally significant for CD4+ (p = 0.036), CD8+ (p = 0.037) 
and FOXp3+ (p = 0.045) cells. No statistically significant 
differences were found regarding premorbid status (perfor-
mance status, ASA grade, age or smoking status, supple-
mental Table S1).
The relationship of TILs and outcome was not statisti-
cally different between patients treated with multimodal 
therapy, NAC and surgery, or surgery alone and is pre-
sented in supplemental Table S1 and supplemental Table 
S3. The distribution of TILs was positively skewed with a 
heavier left than right tail indicating a low proportion of 
patients have high levels of infiltration with lymphocytes. 
The distribution of CD8+ TILs is shown as an example in 
Fig. 1.
The number of TILs positively correlated with each 
other for all subtypes (range of correlation coeffi-
cient = 0.677–0.905; p < 0.001) and is detailed in supple-
mental Table S4.
Prognostic significance of intratumoural infiltrating 
lymphocytes
Median follow-up was 3.5 years with the results of the 
Cox proportional hazard model for predictors of CSS and 
DFS shown in Table 2 and supplemental Table S5, respec-
tively. Multivariate analysis identified independent prog-
nostic factors for improved CSS to be reduced pathologi-
cal N stage (p < 0.0001), higher CD8+ TILs (p = 0.003) 
and completeness of resection (p < 0.0001). The hazard 
ratio for higher number of CD8+ TILs was 0.847 (95 % 
CI 0.760–0.944). Segregation of the TIL data either at 
Fig. 1  Frequency distribution of CD8+ TILs by treatment modality 
highlighting the low proportion of patients with high TIL infiltration
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Table 2  Univariate and 
multivariate Cox regression 
analyses of patient and tumour 
factors with OAC-specific 
survival
Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
Patient factors
 Age 0.987 0.961–1.014 0.348
 Sex
  Female 1 Ref
  Male 1.088 0.495–2.389 0.834
 ASA
  1 1 Ref
  2 1.670 0.659–4.231 0.280
  3 1.398 0.485–4.031 0.535
 Performance status
  0 1 Ref
  1 0.867 0.475–1.580 0.640
  2 0.606 0.199–1.843 0.377
 Preoperative smoker
  No 1 Ref
  Yes 0.835 0.491–1.421 0.507
 Neoadjuvant Rx
  No 1 Ref 1 Ref
  Yes 1.723 1.011–2.937 0.046 1.703 0.977–2.971 0.061
Immunohistochemistry
 CD3 0.966 0.947–0.985 0.001 1.035 0.997–1.075 0.075
 CD4 0.927 0.874–0.982 0.010
 CD8 0.895 0.849–0.944 <0.0001 0.847 0.760–0.944 0.003
 FOXp3+ 0.879 0.801–0.966 0.007
Tumour factors
 ypT or pT stage
  1 1 Ref
  2 2.450 0.947–6.338 0.065
  3 4.480 1.872–10.720 0.001
  4 16.094 4.385–59.071 <0.0001
 ypN or pN stage
  0 1 Ref 1 Ref
  1 4.036 2.033–8.014 <0.0001 3.745 1.806–7.764 <0.0001
  2 6.063 2.889–12.723 <0.0001 3.476 1.515–7.974 0.003
  3 5.143 2.464–10.735 <0.0001 3.607 1.635–7.959 0.001
 ypM or pM stage
  0 1 Ref
  1 4.546 1.402–14.746 0.012
 Vascular invasion
  No 1 Ref
  Yes 2.234 1.354–3.684 0.002
 Lymphatic invasion
  No 1 Ref
  Yes 1.985 1.109–3.554 0.021
 Perineural invasion
  No 1 Ref
  Yes 2.811 1.519–5.201 0.001
 Resection clearance
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Table 2  continued Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
  R0 1 Ref 1 Ref
  R1 3.027 1.737–5.273 <0.0001 3.134 1.699–5.783 <0.0001
Bold values indicate variables of significance
No. at 
risk
Years 0 2 4 6
CD3 
High
65 37 15 5
CD3 
Low
63 29 8 1
No. at 
risk
Years 0 2 4 6
CD8 
High
67 40 17 6
CD8 
Low
61 26 6 0
No. at 
risk
Years 0 2 4 6
Foxp3+ 
High
68 37 15 4
Foxp3+
Low
60 29 8 2
No. at 
risk
Years 0 2 4 6
CD4 
High
66 39 15 4
CD4 
Low
62 27 8 2
Fig. 2  Kaplan–Meier curves of cancer-associated survival revealing prognostic significance of TILs in oesophageal adenocarcinoma
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the medians (low < median or high ≥ median TIL levels) 
allowed Kaplan–Meier survival analysis; the data presented 
in Fig. 2 demonstrate that higher numbers were associated 
with improved CSS. CD8+ TILs ≥ 5 were associated with 
better CSS [CD8+ TILs ≥ 5: mean (median not yet reached) 
CSS 5.1 years, 95 % CI 4.4–5.8, vs. CD8+ TILs < 5: median 
CSS 1.9 years, 95 % CI 1.3–2.4, p < 0.0001].
Multivariate analysis identified independent prognos-
tic factors for reduced DFS as lower CD8+ TIL numbers 
(p < 0.0001), pathological N stage (p < 0.0001), incom-
pleteness of resection (p = 0.001) and multimodal treat-
ment (p = 0.015). The hazard ratio for higher number of 
CD8+ TILs was 0.894 (95 % CI 0.844–0.948). Kaplan–
Meier survival analysis is presented in supplemental Figure 
S2 showing that higher levels of TILs were associated with 
improved DFS. CD8+ TILs ≥ 5 were associated with bet-
ter DFS (CD8+ TILs ≥ 5: mean (median not yet reached) 
DFS 4.7 years, 95 % CI 3.9–5.4, vs. CD8+ TILs < 5: 
median DFS 1.2 years, 95 % CI 0.9–1.5, p < 0.0001).
The relationship of intratumoural infiltrating 
lymphocytes and response to NAC
Significantly higher TIL numbers were found in the tumours 
of patients who had a better pathological response to NAC, 
both when assessing response based on the tumour (TRG) 
and the lymph nodes (downstaging of lymph nodes from 
pretreatment clinical staging to pathological N stage), as 
detailed in Tables 3, 4, supplemental Table S6, supplemental 
Table S7 and supplemental Figure S3. There was a higher 
CD3+ (p = 0.007), CD4+ (p = 0.025) and CD8+ count 
(p = 0.002) in the tumour of patients whose tumour nodal 
status was downstaged at pathological evaluation after NAC. 
Higher TIL frequencies were also seen in patients who had a 
significant pathological response to NAC (TRG2) compared 
to those with no significant response (TRG 3–5) (Table 3).
On multivariate analysis higher CD4+ TIL (p = 0.017) and 
CD8+ TIL densities (p = 0.005) were associated with signifi-
cant tumour response (TRG) and lymph node downstaging, 
respectively, shown in supplemental Table S7 and Table 4.
The relationship of intratumoural infiltrating 
lymphocytes and preoperative systemic inflammatory 
markers
Higher TIL numbers were found in the tumours of patients 
with normal serum albumin although this did not reach 
statistical significance [albumin < 35: CD8+ numbers 
2.00 (0.00–29.30) vs. albumin ≥ 35: CD8+ numbers 6.00 
(0.00–38.00), p = 0.069 (supplemental Table 1)].
Discussion
In this study we have analysed the level of TILs in a large 
homogeneous cohort of oesophagogastric cancer patients 
Table 3  Clinical and pathological factors in OAC patients that 
received chemotherapy (n = 76) based on their response to neoadju-
vant chemotherapy (LN downstaged)
Values in parentheses are percentages unless indicated
* Values in parentheses are range
Bold values indicate variables of significance
Responder n = 30 Non-responder 
n = 46
p value
Age* 63.68 (45.48–
77.75)
62.62 (50.67–
81.28)
0.941
Sex
 Male 29 (96.7) 39 (84.8) 0.101
 Female 1 (3.3) 7 (15.2)
Performance status
 0 8 (26.7) 14 (30.4) 0.446
 1 20 (66.7) 32 (69.6)
 2 2 (6.7) 0 (0)
ASA
 1 5 (16.7) 5 (11.1) 0.859
 2 20 (66.7) 37 (80.0)
 3 5 (16.7) 4 (8.9)
ypT
 1 11 (36.7) 2 (4.3) <0.0001
 2 10 (33.3) 11 (23.9)
 3 9 (30.0) 31 (67.4
 4 0 (0) 2 (4.3)
ypN
 0 30 (100) 3 (6.5) <0.0001
 1 0 (0) 15 (32.6)
 2 0 (0) 15 (32.6)
 3 0 (0) 13 (28.3)
Tumour response
 Yes (TRG2) 11 (36.7) 0 (0) <0.0001
 No (TRG  
3–5)
19 (63.3) 46 (100)
Differentiation
 G1—well 5 (16.7) 37 (80.4) 0.036
 G2—Moder- 
ate
9 (30.0) 1 (2.2)
 G3—poor 16 (53.3) 11 (23.9)
Resection clearance
 R0 2 (6.7) 12 (26.1) 0.034
 R1 28 (93.3) 34 (73.9)
Immunohistochemistry values*
 CD3 15.15 (0.00–44.30) 11.20 (0.00–64.00) 0.007
 CD4 5.00 (0.00–27.00) 2.30 (0.00–20.00) 0.025
 CD8 8.65 (0.00–20.70) 4.50 (0.00–18.70) 0.002
 FOXp3+ 1.85 (0.00–11.30) 1.00 (0.00–9.30) 0.074
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following radical treatment with curative intent. We obtained 
three major findings: firstly, we have shown associations 
between pathological stage of disease and TIL density and 
confirmed the independent association of particular TIL sub-
sets and survival; secondly, we have shown significant cor-
relation between TIL subtypes in OAC, and finally, we found 
patients with a significantly increased pathological response 
to NAC had higher levels of TILs in their resected tumour, 
most notably with CD4+ and CD8+ TILs for local tumour 
regression and lymph node response, respectively.
Of the TIL subsets analysed, CD8+ T cells had the most 
significant independent association for both CSS (p = 0.003) 
and DFS (p < 0.0001). This has been previously suggested to 
be important in OAC; however, independent association has 
not been universally verified [12, 14, 15]. Zingg el al. [15] 
identified on univariate analysis a number of TILs as signifi-
cant predictive factors; however, these were not independ-
ent factors when taking into account the stage of disease. In 
contrast, Schumacher et al. [14] identified CD8+ TILs to 
be a significant predictive factor of survival independent of 
disease stage. The reasons for this discrepancy of findings 
between studies may relate to the clinicopathological factors 
used to build the multivariate statistical model, the location 
of TILs counted and the cut-off values used to dichotomise 
the TIL frequencies into high and low groups. In our large 
and homogeneous cohort, we choose to evaluate TIL num-
ber as a continuous variable, counted intratumoural TILs and 
entered a comprehensive number of known clinicopathologi-
cal predictors of survival into the univariate and subsequent 
multivariate statistical models. We believe this to be the most 
robust analysis of the association of TILs with survival on 
OAC that has been conducted to date.
In addition to the observed effects TILs have on disease 
recurrence, this study demonstrates that TILs play a role 
at different stages of disease. The significant association 
observed between TILs with T and N stage supports the 
possibility that intratumoural T cells prevent tumour pro-
gression throughout the disease process. These findings are 
supported by previous smaller studies showing correlation 
with low TILs and higher stage of disease [14, 15].
A novel observation is that the response to chemotherapy 
links with TIL counts. Previous studies have highlighted 
increased infiltrate of TILs in OAC tumours after NAC when 
compared to surgery alone [13]. We did not find any sta-
tistically significant difference between TIL levels in those 
patients who received NAC and those that proceeded directly 
to surgery as a whole. It would be preferable to evaluate 
TILs in preoperative biopsies to assess response prior to 
neoadjuvant therapy. This was attempted but was unsuccess-
ful due to the paucity of tumour material in the small diag-
nostic endoscopic biopsies unlike the diagnostic biopsies 
taken for other tumours that tend to be larger, for example 
breast and colon cancer. However, different and heterogene-
ous chemotherapy regimens were used in previous studies 
making comparison difficult. We did find that patients who 
had a significant response to NAC (as assessed by TRG and 
LN response) had a higher level of immune infiltrate. This 
important finding has been shown in other cancer sites where 
loss of CD4+ Treg [23] and TIL numbers at the margins of 
liver metastases [24] predicted for response to chemotherapy 
[25–27]. The potential immunological mechanisms by which 
cytotoxic chemotherapy can provide anti-tumour activity 
are being increasingly highlighted. These include: subvert-
ing immunosuppressive mechanisms; exerting stimulatory 
effects in immune cells; and modulating dying tumour cells, 
so they regain visibility to the host immune response [28]. 
The combination of immunological therapies with conven-
tional chemotherapy has been suggested to provide a syner-
gistic effect if the host immunological response is harnessed 
appropriately [29]. In addition to the effects of chemother-
apy on TILs, previous studies have highlighted spontaneous 
pathological regression of tumours in 13.7 % (n = 17/124) 
of OAC cases that have received no NAC when using TRG 
to assess the resected tumour specimen. This may represent 
the host immunological response and successful immune 
attack [30]. Our study would support this hypothesis as sig-
nificant response to NAC was associated with increased TILs 
most notably with CD8+ TILs. In other tumour sites, CD8+ 
infiltration has been shown to correlate with specific immu-
nogenic antigen expression and improved survival [31]. 
These findings highlight the T cell effector potential and a 
means to harness the patient’s immune response in cancer.
It is also of interest that increased frequencies of TILs 
correlate with improved response following the use of 
Table 4  Univariate and 
multivariate analysis of 
immunohistochemical markers 
for response to neoadjuvant 
chemotherapy (LN downstaged) 
in OAC
Bold values indicate variables of significance
Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
CD3 0.957 0.924–0.992 0.015
CD4 0.916 0.838–1.001 0.052
CD8 0.869 0.789–0.958 0.005 0.869 0.789–0.958 0.005
FOXp3+ 0.868 0.734–1.026 0.097
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trastuzumab [32] in light of the ToGA study [33] that may 
lead to the adjuvant use of trastuzumab in OAC. This adju-
vant therapy may lead to a further increase in the adaptive 
immune response in the tumour as seen in breast cancer 
[34]. We have previously shown that patients are more 
likely to respond to chemotherapy if acute phase proteins 
are normal (serum albumin) by assessing systemic mark-
ers of nutrition and the inflammatory response (neutrophil/
lymphocyte ratio, serum albumin) [18]. It is suggested 
that suboptimal immunological and nutritional status may 
contribute to tumour development through subversion of 
tumour immunity [35, 36] and this is particularly perti-
nent to OAC. We found that patients with lower TIL levels 
were less likely to respond to chemotherapy and had lower 
serum albumin levels. From our data, it is not possible to 
know whether high TIL levels lead to a greater responsive-
ness to chemotherapy or chemotherapy leads to a higher 
number of TILs in those that respond, and it may well be a 
combination of the two. The association of poor nutritional 
status with lower TIL levels and a lack of response are logi-
cal and may well be the most likely explanation.
Limitations of this study include its retrospective nature 
and the associated biases on selection and collection. 
Patients were excluded if they had a complete pathological 
response to NAC due to the lack of tumour in the resec-
tion specimen and also if there was insufficient material 
collected. However, this cohort is representative of cur-
rent clinical practice. We found increasing nodal burden 
(p < 0.0001) to be the best independent prognosticator 
for worse survival. The cohort was homogenous in terms 
of staging, histology and treatment algorithms. In addi-
tion, patient, tumour factors and survival data are in keep-
ing with published western cohorts making our findings 
applicable to these populations. The excluded patients with 
complete pathological response (TRG1) potentially will 
have had the highest immune response with high TIL lev-
els. This hypothesis is supported by analysis of the cyto-
toxic response of patients with a complete pathological 
response in breast cancer patients. Granzyme B and TiA1, 
cytolytic granules, expressing cells were observed at higher 
frequency in specimens that had undergone a pathological 
complete response [25].
Additional criticism could be expressed with regard 
to the use of TMA cores not being representative of the 
tumour as a whole. However, multiple studies have utilised 
this approach and excellent correlation between the two 
has been established [37]. With respect to scoring TILs, the 
technique used has been described frequently by other stud-
ies with good interobserver and intraobserver correlation. 
Furthermore, these data were analysed with and without 
dichotomization so as to limit false-positive results [38, 39].
An unexpected finding in our study was the associa-
tion of higher TILs for some subsets (CD4+, CD8+ and 
FOXp3+) in female patients. This may represent a type 
1 error; however, it is well documented that immune cell 
numbers vary with age and gender. Possible explanations 
include the inhibitory effect of oestrogen on T-suppressor 
cells or its stimulatory effect on T helper cells [40]. How-
ever, this speculation is outside the remit of this study and 
will require further analysis. The reason why higher infil-
tration of regulatory FOXp3+ cells showed favourable 
prognosis in this study is complex but has been reported in 
gastric and other tumour types [41, 42]. This warrants fur-
ther functional analysis, but others have suggested a syner-
gistic role of regulatory cells with other TIL subsets within 
the tumour [43].
With regard to our novel finding, it remains to be seen 
whether the composition of TILs can predict for response 
to chemotherapy prior to treatment and the functional role 
the immune response plays in improving the response to 
chemotherapy. Emerging evidence from other solid organ 
tumours suggests that this might be possible [44]. However, 
as yet the required sensitivity and specificity have not been 
met for this to enter clinical practice. A potential clinical 
application of the TIL response could be in the selection of 
patients for specific adjuvant therapies, specifically using 
immunomodulators. In our series, a significant response to 
chemotherapy (TRG2 or LN downstaging) was associated 
with high TIL levels, suggesting these patients may benefit 
from further adjuvant chemotherapy. It would be intrigu-
ing in this group in particular to evaluate the long-term 
outcome after the use of immunomodulators, that release 
pre-existing anti-tumour T cells, as has been proposed for 
aPD1 and aCTLA4 therapies. In contrast, the group of 
patients who had no or a partial response to chemotherapy 
(TRG 3–5 or no LN downstaging) with high TIL levels in 
the pathological specimen additionally may benefit from 
further adjuvant or alternative chemotherapy in combina-
tion with an immunomodulator. In contrast, those patients 
with low TILs may warrant the use of second-line therapies 
but it seems less likely that immune attack will be success-
ful, unless second-line therapy can overcome the barriers to 
immunological visibility of the cancer.
In summary, the results of this study show that local 
immune responses, in particular the adaptive immune 
response, are important independent predictors of CSS and 
DFS in patients with OAC undergoing radical treatment. 
These findings highlight the role of the adaptive immune 
response in preventing tumour recurrence in OAC. A gen-
eralised immune response was observed with high corre-
lation between TIL subtypes and at all stages of disease. 
This is pertinent with regard to the design of therapies as 
it suggests all patients would benefit from treatment that 
appropriately boosts the immune response. A significant 
response was associated with higher infiltration with TILs 
post-therapy. Further work analysing the function of these 
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TIL subsets and the correlation of pretreatment TIL den-
sities with response to therapy may unearth predictors of 
response to chemotherapy in addition to aid design of novel 
treatments or as a mechanism to improve response to cur-
rent therapies.
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